Market Overview

Neuronetics Wins A Sell-Side Bull With Pill-Free Depression Treatment

Neuronetics Wins A Sell-Side Bull With Pill-Free Depression Treatment
Related STIM
The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial
The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study
Immune Design and Community Health Systems among healthcare gainers; Clearside Biomedical leads the losers (Seeking Alpha)

Neuronetics Inc (NASDAQ: STIM) boasts a therapy that addresses a pressing medical need, according to JMP Securities. 

The Analyst

Analyst David Turkaly initiated coverage of Neuronetics with an Outperform rating and $36 price target.

The Thesis

For patients who have failed one of more types of antidepressant medication, Neuronetics' NeuroStar TMS therapy stimulates an exact location on the central or peripheral nervous system with electrical or magnetic energy, Turkaly said in the initiation note. (See the analyst's track record here.) 

The end result is a similar therapeutic impact than what is achieved with pills, but safer, the analyst said. 

Neuronetics' focus on major depressive disorder represents a $10-billion domestic market, according to JMP. 

The market for antidepressant drugs, coupled with the company's differentiated treatment option, should result in a solid growth rate of 20 percent and lift the stock's valuation to a level in-line with the high-growth medical technology sector, the analyst said.

JMP's $36 price target is based on an approximate 7-8 multiple on EV/revenue on expected 2020 sales of $75 million. 

Price Action

Neuronetics shares were down 0.88 percent at $26.02 at the close Monday. 

Related Links:

Tactile Systems' Valuation Is 'Getting Stretched,' BTIG Says In Downgrade

Leerink Downgrades Hologic After 'Lower Quality' Q2 Revenue Beat

Latest Ratings for STIM

Aug 2018JMP SecuritiesMaintainsMarket OutperformMarket Outperform
Aug 2018Canaccord GenuityMaintainsBuyBuy
Jul 2018Canaccord GenuityInitiates Coverage OnBuy

View More Analyst Ratings for STIM
View the Latest Analyst Ratings

Posted-In: David Turkaly JMP SecuritiesAnalyst Color Health Care Price Target Initiation Analyst Ratings General Best of Benzinga


Related Articles (STIM)

View Comments and Join the Discussion!

Boehner-Backed Acreage To Seek CSE Listing, CV Sciences Applies To Nasdaq, PotNetwork Withdraws Form 10

Leerink: Translate Bio's Cystic Fibrosis Candidate Could Generate $1.8B